A comprehensive review of the multisystem benefits of antidiabetic drugs in aging beyond glycemic control

Diabetes management has evolved beyond glycemic control, with emerging evidence demonstrating the multi-system benefits of various anti-diabetic drug classes. This review examines the mechanisms, pharmacokinetics, and therapeutic potential of Glucagon-like Peptide-1 (GLP-1) receptor agonists, Dipeptidyl Peptidase-4 (DPP-4) inhibitors, Sodium- Glucose Cotransporter-2 (SGLT-2) inhibitors, and Thiazolidinediones (TZDs). These agents not only regulate blood glucose but also confer cardiovascular, neuroprotective, renal, and anti-aging effects, positioning them as promising candidates for broader metabolic disorder management. GLP-1 receptor agonists enhance insulin secretion, support weight loss, and exhibit neuroprotective and cardiovascular benefits. DPP-4 inhibitors, which increase endogenous GLP-1 levels, offer stroke prevention and cognitive advantages, particularly in patients with renal impairment. SGLT-2 inhibitors lower blood sugar independently of insulin, reduce heart failure risk, slow kidney disease progression, and possess senolytic properties that may enhance longevity. While TZDs improve insulin sensitivity and beta-cell function, their cardiovascular risks necessitate cautious use. Beyond diabetes, these drugs modulate inflammation, oxidative stress, and metabolic dysfunction—key factors in aging and chronic disease progression. The senolytic potential of SGLT-2 inhibitors, the neurotrophic effects of GLP-1 receptor agonists, and the cardiovascular benefits of DPP-4 inhibitors highlight their broader therapeutic applications. This review underscores a paradigm shift in diabetes management toward a personalized medicine approach. As research advances, integrating these agents into anti-aging and chronic disease prevention strategies may redefine future medical treatments, emphasizing healthier aging and extended lifespan.